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Quantitative real time polymerase chain reaction (qPCR) data are normalised using endogenous 
control genes. We aimed to: (1) demonstrate a pathway to identify endogenous control genes 
for qPCR analysis of formalin‑fixed paraffin‑embedded (FFPE) tissue using bladder cancer as an 
exemplar; and (2) examine the influence of probe length and sample age on PCR amplification 
and co‑expression of candidate genes on apparent expression stability. RNA was extracted from 
prospective and retrospective samples and subject to qPCR using TaqMan human endogenous control 
arrays or single tube assays. Gene stability ranking was assessed using coefficient of variation (CoV), 
GeNorm and NormFinder. Co‑expressed genes were identified from The Cancer Genome Atlas (TCGA) 
using the on‑line gene regression analysis tool GRACE. Cycle threshold (Ct) values were lower for 
prospective (19.49 ± 2.53) vs retrospective (23.8 ± 3.32) tissues (p < 0.001) and shorter vs longer probes. 
Co‑expressed genes ranked as the most stable genes in the TCGA cohort by GeNorm when analysed 
together but ranked lower when analysed individually omitting co‑expressed genes indicating bias. 
Stability values were < 1.5 for the 20 candidate genes in the prospective cohort. As they consistently 
ranked in the top ten by CoV, GeNorm and Normfinder, UBC, RPLP0, HMBS, GUSB, and TBP are the 
most suitable endogenous control genes for bladder cancer qPCR.
Bladder cancer is a major cause of morbidity and mortality in the UK. Data from Cancer Research UK showed 
that it is the tenth most common cancer in the UK, accounting for 3% of all new cancer  cases1. There are multiple 
therapeutic options for bladder cancer, which highlights the importance of developing biomarkers for personalis-
ing  treatment2. Emerging transcriptomic signatures can be progressed towards clinical application using different 
platforms including quantitative real time polymerase chain reaction (qPCR).
qPCR is a sensitive, affordable and efficient method for measuring gene expression in tissue samples including 
formalin fixed paraffin embedded tissue (FFPE). RNA from FFPE is generally of poor  quality3. Formalin fixation 
results in cross-linking of RNA with other macromolecules including DNA and protein which when dissociated 
during RNA purification results in fragmentation and reduction in yield of probable material. Pre-amplification 
of cDNA from these samples is necessary to obtain quantifiable  data4. Samples of cDNA can then be subject 
to qPCR. Most qPCR data measure relative gene expression via normalization with endogenous control genes 
(also known as reference or housekeeping genes). Genes used widely in the past can be affected by tissue type 
and experimental  conditions5–7, and it is important to identify genes with constitutive and invariant expression 
for the samples of interest.
Some studies used multiple endogenous control genes that include several co-expressed genes including the 
ribosomal protein large (RPL) family of  proteins8,9. Where co-expressed genes are present within a candidate gene 
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panel their mutual influence on apparent stability requires consideration. Genes with similar functions tend to 
exhibit similar gene expression  patterns10. Gene co-expression can be checked using the on-line tool Genomic 
Regression Analysis of Coordinated Expression (GRACE) which correlates (Spearman) the expression of a gene 
with all other genes within TCGA. Vandesompele et al.11 propose testing a panel of candidate reference genes 
on a representative number of relevant samples to identify the most stable and optimal number of genes. Test 
data generated are subject to stability assessment algorithms, the two most commonly used are  GeNorm11 and 
 NormFinder12. These algorithms rank genes in order of stability and in the case of GeNorm select the two-gene 
combination that provides the most stable normalization. GeNorm is considered the optimal algorithm for 
studies with small sample  numbers12 but over-rates the stability of co-expressed genes in the candidate panel.
Gene expression data are highly dependent on  platform13 so endogenous control gene selection is carried out 
on the platform of choice. To facilitate selection of control genes, TaqMan endogenous control array cards are 
available with 16 candidate genes. These genes have been used for normalization in human tissue gene expression 
studies including  bladder14,  thyroid15,  hepatocellular16,  breast9,  gastric17,  cervical18,  endometrial19, non-small cell 
 lung20,  kidney21 and  prostate22 cancer. Whilst bioinformatic interrogation of TCGA provides a useful verification 
of gene expression stability it is unsuitable for endogenous control gene selection for TaqMan Array cards as the 
TCGA database is derived using RNA sequencing.
The primary aim of this work is to facilitate selection of endogenous control genes for the Taqman qPCR 
gene expression platform for studies of prospective FFPE cancer tissue using bladder cancer as an exemplar. The 
secondary aim is to evaluate the influence of some covariables including probe length on reverse transcription 
efficiency and co-expression on stability ranking.
Materials and methods
Patient samples. Pre-treatment FFPE grade 3 MIBC samples were available from a prospective (n = 12) 
and retrospective (n = 16) patient cohort. Samples were obtained via the Manchester Cancer Research Centre 
Biobank under research tissue bank ethics (Ref: 18/NW/0092). The cases were graded by an experienced sub-
specialist Uropathologist (HD). Mean (range) block age was 6 (3–8) months for the prospective cohort and 15 
(14–17) years for the retrospective cohort. Two 10 µm sections for RNA extraction and a 4 µm section for his-
tological verification of tumour cellularity (> 30%) were obtained from each block. RNA was extracted from the 
two 10 µm sections using the Roche High Pure FFPET RNA isolation kit. TCGA bladder cancer RNA-seq data 
(n = 401) were also analysed.
TLDA cards and single tube assays. Table 1 lists the endogenous control genes tested along with the 
probes and their amplicon length. Sixteen genes were on the endogenous control TLDA cards and single tube 
assays were set up for succinate dehydrogenase complex flavoprotein subunit A (SDHA) a gene demonstrat-
ing particularly low variability in bladder cancer  cells9. Single tube assays were also run for RPL11, RPL24 and 
GNB2L1 gene to examine the biasing effect of co-expression on gene stability. To investigate the effect of probe 
size on Ct values two different probes were selected for RPL11, RPL24 and GNB2L1.
RNA extraction, quantification and reverse transcription. RNA was extracted using the Roche 
High Pure FFPET RNA isolation kit from two 10 µm sections. The detailed steps of extraction were performed 
according to manufacturer’s recommendations. RNA quantification and purity were determined on a NanoDrop 
UV–Vis Spectrophotometer (Thermo Fisher Scientific Poole UK) and a Qubit fluorometer (Invitrogen Paisley 
UK). Reverse transcription and pre-amplification steps were carried out on a 2720 thermal cycler (Applied Bio-
systems UK). qPCR was carried out on a Quantstudio 12K (Applied Biosystems UK). Complementary DNA 
(cDNA) was generated using a high capacity RNA-to-cDNA kit (Life Technologies Ltd UK). One sample of 
cDNA was subject to pre-amplification using a custom preamp pool mix consisting of gene expression assay cor-
responding with genes present on the TaqMan human endogenous control card array (Applied Biosystems®). A 
further sample of cDNA underwent pre-amplification using a preamp pool mix prepared by mixing single tube 
assay (Thermo Fisher Scientific UK) components for the panel of candidate genes not present on the endogenous 
control card array. A preamp TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific UK) was used for 
both samples. The pre-amplification step was carried out for 14 cycles on a 2720 thermal cycler.
qPCR. Samples pre-amplified using the control array primer pool were mixed with Fast Mastermix (2X) and 
loaded onto the endogenous control plate and subject to qPCR on a Quantstudio12 (Applied Biosystems). Sam-
ples pre-amplified using the pooled single assay primer pool were loaded into 96 well plates preloaded with indi-
vidual gene probes and Fast Mastermix (2x) and subject to qPCR on a Quantstudio12 using the fast cycle option.
Data analysis. TCGA was accessed using the Firebrowse portal selecting RSEM normalised RNAseq blad-
der cancer. Each gene was examined for co-expression with other genes within the candidate panel using the 
on-line tool GRACE. Coefficient of variation (CoV) values for the expression of each gene were calculated and 
significant differences between mean values determined using the Student t-test.
GeNorm (https ://genor m.cmgg.be/) and Normfinder (NormFinder software—moma.dk) algorithms were 
used to determine the most stable genes from the list of candidates. The software packages were used as excel add-
ons. To determine the biasing effect of co-expressed genes on apparent gene expression stability using GeNorm, 
the analyses were carried out with all candidate genes and repeated after removing 3 of the 4 co-expressed genes.




Scientific Reports |        (2020) 10:17258  | https://doi.org/10.1038/s41598-020-74380-7
www.nature.com/scientificreports/
Results
RNA yield, quality and expression reliability. The mean (range) yields were 291 (50–560) ng/µl for the 
12 prospective and 251 (64–425) ng/µl for the 16 retrospective samples. The mean (range) RNA quality ratios 
were 1.90 (1.93–2.19) for 260/280 and 2.00 (1.72–2.12) for 260/230 for the prospective samples. Respective 
values for retrospective samples were 1.88 (1.56–1.98) and 1.73 (1.53–2.00). Gene expression was determined 
in triplicate and the intra-sample standard deviation (SD) of the cycle threshold (Ct) values (number of cycles 
required for the fluorescent signal to cross a threshold) calculated for the 28 samples. Table 1 lists the mean SD 
for each of the 23 candidate endogenous control gene probes. The mean ± SD of the SD of the Ct values for trip-
licate assays for 16 endogenous control genes assayed in 28 samples on TaqMan arrays was 0.153 ± 0.071 (n = 448 
gene-probe/sample combinations; range 0.079 to 0.37). For the 7 single tube assays the mean SD for the Ct values 
were 0.082 ± 0.022 (n = 196 gene-probe/sample combinations; range 0.046 to 0.129). To investigate inter-assay 
reliability three samples were assayed by qPCR on two separate TaqMan arrays/96 well plates run on two dif-
ferent days. The mean ± SD of the SD of the Ct values for each gene/sample (n = 48) was 0.21 ± 0.04 for samples 
loaded onto TLDA cards and 0.07 ± 0.039 for the single tube assays loaded into 96 well plates.
Effects of FFPE block age and gene probe length. Table  2 lists the mean, SD and CoV of the Ct 
values for each of the 23 (16 on the TLDA array card and 7 single assay) gene probes assayed in the prospective 
and retrospective patient cohorts. The mean Ct values for all 23 probes were significantly lower when assayed 
in the prospective compared with the retrospective cohort (p < 0.0001). Figure 1 shows the mean Ct values for 
two probes of different lengths for RPL11, RPL24 and GNB2L1. Ct values were significantly higher (significance 
levels indicated in Fig. 1) with the longer probes, except for GNB2L1 in the prospective samples. Shorter length 
gene probes for these genes were selected for subsequent analyses. 
Gene stability. Table 3 lists the candidate endogenous genes by stability as determined by CoV, GeNorm 
and NormFinder in the prospective (n = 12) and TCGA (n = 401) bladder cohorts. Figures 2 and 3a plot the 
candidate endogenous gene stability ranking by GeNorm in the prospective and TCGA cohorts respectively. 
GeNorm also defines the stability value for the combination of the two most stable genes. All candidate genes 
were expressed stably with values below the recommended M = 1.5 cut-off. In the prospective cohort GeNorm 
identified the combination of SDHA and IPO8 as the most stable. Five  genes (UBC, RPLP0, HMBS, GUSB, 
and TBP) were present in all the ten most stable genes ranked by CoV, GeNorm and NormFinder. In the TCGA 
cohort PPIA and TBP had the greatest stability by both CoV and NormFinder. However, GeNorm ranked the 
four co-expressed genes RPLP0, RPL11, RPL24 and GNB2L1 (Fig. 3) as exhibiting the most stable expression. 
Interestingly the next two genes were PPIA and TBP.  
Table 1.  Candidate endogenous control genes with the Thermo Fisher gene probe, amplicon length and 
intra-assay reliability.  Reliability was measured as intra-sample standard deviation (SD) of cycle threshold (Ct) 
values assayed in triplicate. Each probe was assayed in 28 samples and the mean of the SD values calculated.
Candidate gene Gene probe Amplicon size (bp) Intra-sample Ct SD
18S rRNA 18S-Hs99999901_s1 187 0.250
ACTB ACTB-Hs99999903_m1 171 0.370
B2M B2M-Hs99999907_m1 75 0.083
GAPDH GAPDH-Hs99999905_m1 122 0.163
GUSB GUSB-Hs99999908_m1 81 0.108
HMBS HMBS-Hs00609297_m1 64 0.090
HPRT1 HPRT1-Hs99999909_m1 100 0.232
IPO8 IPO8-Hs00183533_m1 71 0.247
PGK1 PGK1-Hs99999906_m1 75 0.323
POLR2A POLR2A-Hs00172187_m1 61 0.150
PPIA PPIA-Hs99999904_m1 98 0.150
RPLP0 RPLP0-Hs99999902_m1 105 0.101
TBP TBP-Hs99999910_m1 127 0.136
TFRC TFRC-Hs99999911_m1 105 0.095
UBC UBC-Hs00824723_m1 71 0.106
YWHAZ YWHAZ-Hs00237047_m1 70 0.084
SDHA Hs00188166_m1 70 0.065
RPL11 Hs00831112_s1 142 0.129
RPL11 Hs04183527_g1 106 0.117
RPL24 Hs02338570_gH 156 0.091
RPL24 Hs07291664_gH 86 0.058
GNB2L1 Hs00914568_g1 75 0.095
GNB2L1 Hs00272002_m1 66 0.046
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Table 2.  Comparison of inter-sample gene expression in the prospective and retrospective cohorts. Mean 
(Ct), inter-sample SD and inter-sample CoV in gene expression (Ct) in FFPE tissue from prospective (12 
samples) and retrospective (16 samples) bladder cancer cohorts.  *The p values are from a Mann Whitney test 
comparison of mean Ct values in the prospective and retrospective data.
Gene
Prospective samples (n = 12)
Retrospective samples 
(n = 16)
P value*Mean Ct SD CoV (%) Mean Ct SD CoV (%)
TaqMan™ endogenous control array
`18S rRNA 23.29 1.71 7.60 30.43 2.39 7.86 4.60E−07
ACTB 22.09 1.26 5.71 29.50 4.85 16.47 9.20E−06
B2M 16.27 0.75 4.62 20.11 1.56 7.80 6.57E−08
GAPDH 18.51 1.19 6.44 23.44 2.18 9.29 7.53E−07
GUSB 20.15 0.86 4.25 24.06 1.56 6.49 2.63E−07
HMBS 23.08 0.96 4.18 25.58 1.21 4.71 2.95E−06
HPRT1 22.35 1.23 5.49 29.61 5.36 18.09 9.17E−07
IPO8 20.48 0.71 3.45 23.87 1.12 4.70 6.57E−08
PGK1 17.31 0.82 4.75 20.80 1.44 6.95 7.89E−07
POLR2A 19.37 0.70 3.59 21.99 0.80 3.64 6.57E−08
PPIA 16.71 1.10 6.59 20.38 1.59 7.78 2.63E−07
RPLP0 18.15 1.10 6.02 22.59 1.94 8.60 1.31E−07
TBP 25.57 1.13 4.40 31.92 4.16 13.03 9.17E−06
TFRC 20.40 1.20 5.88 23.85 1.50 6.28 7.89E−07
UBC 16.94 0.88 5.24 20.35 1.18 5.80 6.57E−08
YWHAZ 21.90 0.98 4.49 24.99 1.57 6.29 2.63E−07
Single tube assay
SDHA (70) 20.18 0.81 4.00 23.00 1.37 6.00 1.28E−05
RPL11 (142) 18.90 1.17 6.17 24.53 2.50 10.2 2.63E−07
RPL11 (106) 17.40 1.06 6.09 21.91 1.91 8.70 2.63E−07
RPL24 (156) 19.00 1.19 6.30 24.93 2.43 9.75 1.32E−07
RPL24 (86) 16.69 1.02 5.78 20.26 1.52 7.47 2.63E−07
GNB2L1 (75) 17.17 0.99 5.24 21.50 1.69 7.86 6.57E−08



































**                                        **                                       *   
Figure 1.  Benefit of selecting shorter probes for candidate endogenous control genes. Histograms show the 
mean ± SD of cycle threshold (Ct) values and the x-axes show the genes. (Long probes (solid columns) RPL11 
142 bp; RPL24 156 bp; GNB2L1 75 bp. Short probes (empty columns) RPL11 106 bp; RPL24 86 bp; GNB2L1 66 bp). 
Asterisks indicate the level of significance for differences in Ct values by probe length (*P < 0.05; **P < 0.01; ns not 
significant). (a) RPL11 (p = 0.0056), RPL24 (p = 0.00086) and GNB2L1 (p = 0.76) assayed in 12 prospective samples. 
(b) RPL11 (p = 0.0058), RPL24 (P = 0.00000228) and GNB2L1 (p = 0.00054) assayed in 16 retrospective samples.
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To explore the possibility of bias due to co-expression GeNorm analysis was carried out omitting 3 of the 4 
co-expressed genes. Figure 3 shows that when 3 of the 4 co-expressed genes were excluded from the analysis, 
expression levels of PPIA and HPRT1 were the most stable with TBP and HMBS in third and fourth place. 
Co-expression accounts for some of the apparent high stability of these four genes when analysed collectively 
alongside all candidate genes by GeNorm. However, when analysed in the absence of co-expressing genes, RPL11 
and RPL24 rank sixth, RPLP0 seventh and GNB2L1 tenth suggesting that their expression is sufficiently stable 
to use as endogenous controls.
Assessing the performance of the selected endogenous control genes. Genes in the bladder 
cancer cohort extracted from the TCGA were ordered by CoV and the candidate endogenous genes highlighted 
(Fig. 4). All the candidate endogenous control genes fell within the lower 50% of CoV values. The most stable 
Table 3.  Gene stability ranking: The ten most stable genes selected on the basis of lowest CoVs, or by 
inputting Ct values into GeNorm and Normfinder algorithms from the prospective bladder cancer cohort and 
TCGA bladder cancer cohort. (*’common’ refers to genes which appear in the top ten most stable genes in all 
three measures of stability (CoV, GeNorm and Normfinder)).
Rank CoV GeNorm NormFinder Common*
Prospective bladder cancer cohort
1 SDHA SDHA HMBS UBC
2 IPO8 IPO8 PGK1 RPLP0
3 POLR2A UBC UBC HMBS
4 HMBS GUSB GAPDH GUSB
5 GUSB RPLP0 PPIA TBP
6 TBP HMBS GUSB
7 UBC PPIA TBP
8 RPLP0 RPL11 GNB2L1
9 HPRT1 GAPDH RPLP0
10 YMHAZ TBP HPRT1
TCGA bladder cancer cohort
1 TBP RPL11 PPIA TBP
2 PPIA RPL24 TBP PPIA
3 IPO8 GNB2L1 UBC HMBS
4 UBC RPLP0 IPO8 RPL11
5 POLR2A PPIA RPL11
6 RPL11 TBP HMBS
7 ACTB HPRT1 SDHA
8 YWHAZ HMBS GAPDH
9 HMBS GUSB RPLP0



























Figure 2.  Plot of average expression stability values (M) of remaining candidate endogenous genes during 
stepwise removal of the gene least stable gene by GeNorm. Data are for 12 prospective samples and the order of 
the genes on the x-axis indicate their ranking with the least stable on the left. Successful exclusion of the least 
stable gene by determining the expression ratios of each gene paired with each of the other genes leads to a 
combination of the two most stably constitutively expressed genes (in this case HMBS and POLR2A).
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seven genes (TBP, PPIA, UBC, IPO8, POLR2A, RPL11 and ACTB) are within the lowest 20% CoV values. Fig-
ure 5 shows the most stably expressed endogenous control genes have coordinated changes in Ct values when 
assayed in different samples showing they are influenced similarly by differences in RNA quality, reverse tran-





































































































































































































































































































Figure 3.  Influence of co-expressed genes on apparent gene expression stability. Plot of average expression 
stability values (M) of remaining candidate endogenous genes during stepwise removal of least stable genes by 
GeNorm based on TCGA sample cohort. All candidate endogenous control genes present in the analysis (a) 
excluding RPLP0, RPL11 and RPL24 (b) excluding GNB2L1, RPL11 and RPL24 (c) excluding GNB2L1, RPLP0 
and RPL24 (d) excluding GNB2L1, RPLP0 and RPL11 (e).
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Figure 4.  Plot of gene expression CoV for TCGA bladder cancer cohort (n = 401 samples) highlighting 
candidate endogenous control gene panel: TBP (A), PPIA (B), IPO8 (C), UBC (D), POLR2A (E), RPL11 (F), 
ACTB (G), YMHAZ (H), HMBS (I), RPL24 (J), GNB2L1 (K), RPLP0 (L), GAPDH (M), PGK1 (N), GUSB (O), 
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Figure 5.  Co-ordination between candidate endogenous control gene expression in prospective bladder cancer 
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Discussion
Measuring gene expression is increasingly important for a diverse range of clinical  applications23–26. Purification 
of RNA, an essential prerequisite for qPCR, removes other cellular components and data must be normalised 
based on the stable expression of endogenous control genes. Analysis of gene expression studies showed using 
a single endogenous control  gene11 can produce gene expression error values of over 20-fold suggesting that 
multiple endogenous control genes are required for normalisation.
Selection of endogenous control genes needs to be rigorous and take account of potential confounding factors 
which may be study specific. Commonly used endogenous control genes shown to be stable in one tissue type 
and set of conditions may be unsuited for others. GAPDH and β-actin and suitable for qPCR normalisation in 
some situations because they are expressed at high and constant levels in many cells and  tissues27,28. However, 
a study using GAPDH and ACTB as endogenous control genes demonstrated aberrations in qPCR results due 
to the regulatory effects of microRNAs on the expression of these  genes7. Further, the expression of GAPDH 
correlates highly with CA9, a marker of hypoxia, precluding the use of GAPDH as an endogenous control gene 
for studies involving solid tumours.
In this study we have described a workflow that uses a combination of laboratory and software tools to select 
a set of endogenous control genes for qPCR studies. The protocol is summarised in Fig. 6.
Both GeNorm and Normfinder can identify the most stable from the least stable endogenous control  genes29. 
However, in common with other  studies30,31 the order of gene stability ranking by the two algorithms differed for 
both the prospective and TGCA cohorts. GeNorm uses pairwise comparison of candidate endogenous control 
genes to test for gene expression  stability11 to stepwise eliminate the least stable genes. NormFinder is a math-
ematical model based on ANOVA which calculates an overall average expression level for all genes to which 
it compares the expression of each individual gene and ranking according to  stability12. For small sample size 
studies GeNorm is recognised as the more reliable algorithm for determining gene expression  stability29. On 
the other hand, Normfinder is considered more robust than GeNorm for studies with larger sample numbers. 
GeNorm can preferentially select genes that are coregulated which mutually reinforce and so bias the apparent 
expression stability of co-expressed genes.
Using GeNorm, POLR2A and HMBS were identified as the most stable gene combination in the prospec-
tive sample cohort. GeNorm but not Normfinder ranked the four co-expressed genes as the most stable of the 
candidate group when analysed in the TCGA cohort. To test the possibility that GeNorm was selecting these 
genes due to bias through co-expression the analysis was repeated excluding 3 of the 4 co-expressed genes in our 
endogenous control gene panel. In each case the remaining gene remained within the top ten genes but ranked 
lower. This finding suggests that these genes can still be used for normalisation but when analysed together using 
GeNorm multiple co-expressed genes can provide mutual reinforcement in stability score which overstates their 
actual stability, at least in part, explaining the difference of the overall endogenous control ranking by GeNorm 
and Normfinder.
Select candidate genes based on a 
literature search of control genes 
used in tumour type of interest to 
supplement an endogenous 
control gene panel 
Check for gene co-expression using 
hps://grace.biohpc.swmed.edu/An
alysis.php
Collect tumour ssue samples 
(>10 paents) ensuring tumour 
cellularity is >30% 
Select probes for at least 15 
independently expressed candidate 
genes minimising probe length and 
avoiding exon to exon boundaries. 
Determine expression data in 
clinical samples using plaorm of 
interest 
Select genes with the highest 
stability based on CoV and output 
from GeNorm and Normfinder  
Final selecon based on genes 
that consistently perform in the 
top 10 most stable genes by each 
analysis 
Confirm stability by analysing the candidate genes in the relevant tumour cohort in 
TCGA to assess stability and produce a visual display of the co-ordinaon between 
gene expression in each sample 
Figure 6.  Steps involved in selection of endogenous control genes for normalisation of FFPE tumour tissue.
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Interestingly GeNorm did not rank the co-expressed genes highly in the prospective muscle invasive bladder 
cancer cohort. Overall ranking of the endogenous control genes by both GeNorm and Normfinder differ between 
the two cohorts. These different rankings are not surprising as gene expression data in TGCA is acquired using 
RNAseq and normalised. Gene expression data in the TCGA is also acquired using RNA extracted from fresh-
frozen tissue which will be less modified than that from FFPE. However, it has been shown that RNA expres-
sion acquired using FFPE maintains the fidelity of patterns in biological signals and relationships with patient 
outcomes consistent with studies using fresh-frozen  tissue32.
Taqman PCR gene expression methodology requires complete hybridisation of gene probes to cDNA 
sequences to register a hit which would suggest that shorter gene probe sequences will improve gene expression 
detection especially in degraded samples. Consistently Ct values were found to be significantly lower compared 
with long probes when using shorter gene probes for RPL11, RPL254 and GNB2L1 demonstrating the importance 
of choosing shorter length probes to reduce the risk of sample gene dropout especially when using archived 
FFPE samples.
In summary, our work highlights the importance of probe length and the need to account for co-expression 
when selecting a panel of endogenous control genes for downstream application in clinical samples. We identified 
a set of six genes that are stably expressed in FFPE bladder cancer samples and are suitable for use as endogenous 
control genes. We also recommend use of our workflow to harmonise the process of endogenous control selec-
tion qPCR-based studies.
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